Your trusted source for investing success

Tag: overdose

RespireRx Pharmaceuticals Inc. to Present at 2017 Rodman & Renshaw Conference

RespireRx Pharmaceuticals Inc. to Present at 2017 Rodman & Renshaw Conference

RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of respiratory disorders, including sleep apnea, opioid-induced respiratory depression, and respiratory insufficiency due to spinal cord injury, announces that the Company’s Chief Executive Officer and Vice Chairman of the Board of Directors, James

Intellipharmaceutics Announces 2016 Year End Results

TORONTO, Feb. 10, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2016. 

Intellipharmaceutics Submits New Drug Application for Rexista®

Intellipharmaceutics International, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has filed a New Drug Application seeking authorization to market its Rexista.

Intellipharmaceutics Announces Third Quarter 2016 Results

Intellipharmaceutics International, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2016.

Insys Therapeutics Announces First Patient Enrolled in Phase II Trial for the Treatment of Cocaine Dependence Using Pharmaceutical Cannabidiol

PHOENIX, Aug. 18, 2016 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol (CBD) product candidate. The study is being conducted by Dr. Didier Jutras-Aswad,

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
The Basics of the Graphene Market

URL: https://investingnews.com/daily/tech-investing/graphene-investing/analyst-interview-top-trends-in-graphene-investing/